Table 1.
Baseline characteristics
| Characteristics (n = 15) | Mean (SD) or n (%) |
|---|---|
| Age, years | 48 (6.9) |
| Sex | |
| Male | 13 (86.7) |
| Race and ethnicity | |
| Black | 7 (46.7) |
| Hispanic white | 6 (40.0) |
| Non‐Hispanic white | 2 (13.3) |
| Self‐identified major risk factor for HIV infection | |
| MSM | 9 (60.0) |
| Homosexual | 5 (33.3) |
| i.v. drug use | 1 (6.7) |
| Co‐encapsulated ARV | |
| TAF/FTC | 6 (40.0) |
| EVG/COBI/FTC/TAF | 1 (6.7) |
| TAF/FTC/RPV | 3 (20.0) |
| ABC/3TC/DTG | 5 (33.3) |
| Most recent CD4 count, cells/uL [min, max] | 774.2 [275, 1375] |
| Most recent plasma HIV RNA | |
| < 20 copies/mL | 10 (66.7) |
| ≥ 20 copies/mL | 4 (26.7) |
| Unknown | 1 (6.7) |
ABC/3TC/DTG, abacavir/lamivudine/dolutegravir; ARV, antiretroviral; EVG/COBI/FTC/TAF, elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine; MSM, Men who have sex with men; TAF/FTC, tenofovir alafenamide/emtricitabine; TAF/FTC/RPV, tenofovir alafenamide/emtricitabine/rilpivirine.